Efficacy and Safety of Cilostazol for the Indication of CSPS

Post Marketing Surveillance of Efficacy and Safety of Cilostazol for the Indication of CSPS

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00216749

Enrollment

650

Registered

2005-09-22

Start date

2003-12-31

Completion date

2007-10-31

Last updated

2009-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Infarction

Keywords

Cerebral Infarction Prevention, Cilostazol

Brief summary

This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.

Detailed description

This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction. Qualified patients will be treated with cilostazol by physician's assessment. This study will be continued for 4 years. More than 600 patients for 4 years.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patient with an experience of cerebral infarction and having a purpose for prevention of recurrence of cerebral infarction. * Age: more than 18 years of age

Exclusion criteria

* Unqualified patients judged by study investigator(s)

Design outcomes

Primary

Measure	Time frame
1)Efficacy:Recurrence of cerebral infarction 2)Safety:Adverse Event	3M

Countries

South Korea

Outcome results